NYCDoc29

ASCO, ASH, EHA & ESMO Member - fr FT academic, traveller, foodie & now private practice! #girldad #boydad #hematology #oncology

[NYCDoc29 @nycdoc29]

@SrihariNaiduMD @purviparwani @baileyannRN @docbhardwaj @JamalRanaMD @seiiwaiEPmd @DNFeldmanMD @adityadoc1 @djc795 @CMichaelGibson @LindsayLuvDavis Happy Father’s Day! I know the journey!

[Lymphoma Hub @lymphomahub]

CONGRESS #EHA2024 | Primary analysis of the phase II ELM-2 study demonstrates deep and durable responses with odronextamab (CD20×CD3 bispecific antibody) in heavily pretreated pts with R/R FL. Primary endpoint ORR, 80%; CR rate 73%; CR correlated with favorable PFS and OS at 24 mo. Patients with low/undetectable CD20 expression achieved CR. CRS events were mostly low grade. #lymphoma #lymsm #MedicalCongress

[NYCDoc29 @nycdoc29]

very impressive so far #mmsm #myeloma #EHA24 #EHA2024 $ACLX

[Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽 @Rfonsi1]

Anito-cel is quite iteresting. D Domain making binding of target more specific? Limited CRS and no delayed MNT. ORR 100%. Small series but quite intriguing. Could it be that binding specificity is the ultimate secret?
#EHA24RF #msmm

[Annamaria Brioli @abrioli]

Impressive PFS with the quadruplet combination in NTEMM…but balancing efficacy and tolerability is key in the elderly. Great plenary presentation by Prof Facon #EHA2024

[Graham Collins @graham74GC]

Galtier - outcome of PMBCL with CAR-T (Descar-T data)
- 55 axi-cel pts
- 80% CMR
- 2y PFS 68.7%
- CRP > 30 prognostic
- LDH / briding response NOT prognostic
Excellent outcomes! Encouraging.
#EHA2024 #lymsm

[Lymphoma Hub @lymphomahub]

CONGRESS #EHA2024 | Arnon P. Kater @amsterdamumc shared early results of the EPCORE CLL-1 trial of epcortitamab in Richter's transformation (RT). N=35, mFU=8.1 mo, ORR was 53% (60% & 44% in 1L RT & 2L RT, resp), CR rate was 42% (50% & 33% in 1L RT & 2L RT, resp), OS was 11.7 mo, non-hematologic TEAEs were of mainly low grade (Gr 1-2). CRS was mostly low grade. #lymphoma #lymsm #leusm #medicalcongress #hematology

[Fernando Martín Moro @Fer_martinmoro]

Glofitamab monotherapy as salvage therapy in heavily pretreated mantle cell #lymphoma

With @amniebla as chair-@WomenInLymphoma of the session! 💪 @geltamo

#EHA2024

[NYCDoc29 @nycdoc29]

@OmarNadeemMD nice to see another option beside talquetamab #myeloma #mmsm #EHA24 - would love to see future development in trials tease out "differences"

[Ingrid Glimelius @glimelius]

#EHA24, Bories Pierre
Real world data on elderly>75 with CAR-t versus younger.<75
Bias of selection likely but as good as for younger. So we can treat also the old 😊 increased risk of infections!!

[𝗡𝗶𝗵𝗮𝗿 𝗗𝗲𝘀𝗮𝗶 MD, DM @nihardesai7]

Do check out our multicentre collaboration from 🇨🇦 at #EHA24 👍🏼

Belumosudil shows promise in treating patients with heavily pre-treated moderate-severe cGVHD.

Median of 5 prior lines of Rx (all Rux exposed)

Median of 3 affected organs at start of Rx

FFS 6m: 72%

#EHA24

[NYCDoc29 @nycdoc29]

taken along with TRANSFORM-1 looks like single agent JAK2i maybe out in frontline MF. #EHA24 #MPN

[Prithviraj Bose @bose_prithviraj]

Important updates to MANIFEST 2 presented by @RaajitRampal at #EHA24 beyond what was presented at #ASH23 @bose_prithviraj @harrisoncn1 #johnmascarenhas @Vikas_Gupta_1 @KuykendallMd @AaronGerds @mpdrc @mpndoc @pankitvachhani

[NYCDoc29 @nycdoc29]

@rajshekharucms wonder IF a subgroup of patients drove results? high-risk cytogenetics? subsequent #CART treatment? #EHA24 #MMSM #myeloma

[NYCDoc29 @nycdoc29]

@doctorpemm @EHA_Hematology @harrisoncn1 @mpdrc @jjkiladjian @RaajitRampal @PedsHemeDoc @mpndoc @KuykendallMd @GabyHobbs @mtmdphd @mdmajmudar @KMirza Will single agent JAK2i be out? TRANSFORM-1 looks like it will "transform" MF treatment in frontline. #EHA24 #MPNSM $INCY

[Naveen Pemmaraju, MD @doctorpemm]

👉👉👉Honored to present #EHA24 #EHA2024 today 👉#TRANSFORM-1 results randomized ph3 clinical trial. RUXO+#NAVITOCLAX frontline vs RUXO+placebo n=252, Med f/u 20.3 mo. SVR35w24= 63.2% NaV+RuXo vs 31.5% in RUXO+PLCBO ➡️Primary Endpoint met| #MPNSM @EHA_Hematology @harrisoncn1

[Raj Chakraborty @rajshekharucms]

Always nice to see long-term follow up results! Dr. Moreau pointed out that >80% of patients in Dara-VTD arm of CASSIOPEIA are alive at 8 years despite half of them getting no maintenace! Exciting prospects indeed for limited duration therapy in #MultipleMyeloma!
#EHA24

[Talha Badar @TalhaBadarMD]

#EHA2024 #EHA24 #MPN_PV

Palandri: state of the art talk on PV

1) 4 must-dos in all pts.

2) timely intervention, moving to 2nd line therapy appropriately, nice algorithm 👇🏽

3) Role of hepcidin analogues.

[NYCDoc29 @nycdoc29]

@amarkelkar @marklewismd its more politics - state boards are filled with appointees by governor. NO governor wants to lose this additional influence over #healthcare - its a place to reward supporters

[NYCDoc29 @nycdoc29]

#MedTwitter - licensing currently is state issued & controlled by state boards which are highly political. Nobody wants to ceed their fief & governors don't want to lose control. #telehealth

[Tatiana Prowell, MD @tmprowell]

📣📣📣

We need permanent #telehealth coverage & either a single national license or universal interstate reciprocity of licensure for clinicians now!

#MedTwitter #NurseTwitter & patients, call your Congresspeople & tell them you want this: 202-224-3121.

[Aakash Desai, MD, MPH, FASCO @ADesaiMD]

LAURA Ph 3: Osimertinib vs Placebo #ASCO24 @ASCO

➡️ mPFS: 39.1 vs 5.6 mo (HR 0.16) ‼️
➡️ 24-mo PFS: 65% vs 13% 📈
➡️ 81% received osi at progression 💊, Good!
➡️AE discontinuation**: 13% vs 5% ⚠️

Can't wait for @RamalingamMD's presentation today! 🎤 #ASCO24 @OncoAlert Data courtesy: @FordePatrick’s tweet! @OncoAlert

[Paolo Tarantino @PTarantinoMD]

Antonio Giordano (@antgiorda) from @DFCI_BreastOnc presents the first data of the Nectin4 ADC enfortumab vedotin in metastatic breast cancer. ORR 15.6% in HR+ and 19% in TNBC, PFS 5.4 and 3.5 months, respectively. Nectin4 expression not predictive of benefit with EV. #ASCO24